BRPI0416987A - direcionamento de antìgenos de erb - Google Patents

direcionamento de antìgenos de erb

Info

Publication number
BRPI0416987A
BRPI0416987A BRPI0416987-5A BRPI0416987A BRPI0416987A BR PI0416987 A BRPI0416987 A BR PI0416987A BR PI0416987 A BRPI0416987 A BR PI0416987A BR PI0416987 A BRPI0416987 A BR PI0416987A
Authority
BR
Brazil
Prior art keywords
erb
binder
affinity
biotin
ligand
Prior art date
Application number
BRPI0416987-5A
Other languages
English (en)
Inventor
Bengt E B Sandberg
Rune Nilsson
Original Assignee
Mitra Medical Technology Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0303229A external-priority patent/SE0303229D0/xx
Application filed by Mitra Medical Technology Ab filed Critical Mitra Medical Technology Ab
Publication of BRPI0416987A publication Critical patent/BRPI0416987A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

DIRECIONAMENTO DE ANTìGENOS DE ERB. A presente invenção refere-se a um conjugado compreendendo a) porção de ligação com cruzamento trifuncional, à qual é acoplado, b) um ligante de afinidade através de um ligante 1, c) um agente citotóxico, opcionalmente através de um ligante 2 e d) um anticorpo anti-Erb ou suas variantes tendo a habilidade de se ligar a antígenos de Erb expressos em superfícies de tumor de mamífero com uma constante de ligação de afinidade de pelo menos 5X 10¬ 6¬ M¬ -1¬, onde o ligante de afinidade é biotina ou uma derivado de biotina tendo essencialmente a mesma função de ligação à avidina ou estreptavidina que a biotina, onde a estabilidade com relação à clivagem enzimática da ligação biotinamida foi introduzida no ligente 1.
BRPI0416987-5A 2003-11-28 2004-11-26 direcionamento de antìgenos de erb BRPI0416987A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52570303P 2003-11-28 2003-11-28
SE0303229A SE0303229D0 (sv) 2003-11-28 2003-11-28 Targeting of Erb antigens
PCT/SE2004/001753 WO2005051424A1 (en) 2003-11-28 2004-11-26 Targeting of erb antigens

Publications (1)

Publication Number Publication Date
BRPI0416987A true BRPI0416987A (pt) 2007-08-21

Family

ID=34635770

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416987-5A BRPI0416987A (pt) 2003-11-28 2004-11-26 direcionamento de antìgenos de erb

Country Status (11)

Country Link
US (1) US20080267865A1 (pt)
EP (1) EP1708750A1 (pt)
JP (1) JP2007512324A (pt)
KR (1) KR20070003806A (pt)
AU (1) AU2004292933B2 (pt)
BR (1) BRPI0416987A (pt)
CA (1) CA2547435A1 (pt)
MX (1) MXPA06006009A (pt)
NO (1) NO20062410L (pt)
RU (1) RU2006122952A (pt)
WO (1) WO2005051424A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666184A1 (en) * 2006-10-11 2008-04-17 Medvet Science Pty. Ltd. The use of a dna damaging agent and a ligand for the treatment of cancer
EP2604283A1 (en) 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
US8535639B2 (en) 2007-07-17 2013-09-17 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging
PT2291659E (pt) * 2008-05-13 2016-01-22 Univ Yale Moléculas quiméricas pequenas para o recrutamento de anticorpos contra células cancerosas
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
WO2010055950A1 (ja) 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
WO2011071447A1 (en) * 2009-12-10 2011-06-16 Nicholls Ian A Molecular imprints
GB201205360D0 (en) 2012-03-27 2012-05-09 Univ Edinburgh Biotinidase resistant biotinyl compounds
JP2021525737A (ja) 2018-05-30 2021-09-27 ザップ サージカル システムズ， インコーポレイテッド 重要構造近くにおける放射線外科的神経調節

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630978A (en) * 1995-06-07 1997-05-20 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Preparation of biologically active molecules by molecular imprinting
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
US7141676B1 (en) * 1996-02-08 2006-11-28 University Of Washington Water soluble multi-biotin-containing compounds
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
US20050271673A1 (en) * 1998-07-07 2005-12-08 Wilbur D S Trifunctional reagent for conjugation to a biomolecule
BRPI0012196B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
AT500848B1 (de) * 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
SE0002287D0 (sv) * 2000-06-16 2000-06-16 Department Of Radiation Oncolo Biotinderivat
WO2003035011A2 (en) * 2001-10-26 2003-05-01 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
SE0203731D0 (sv) * 2002-12-13 2002-12-13 Mitra Medical Technology Ab Reagent

Also Published As

Publication number Publication date
EP1708750A1 (en) 2006-10-11
AU2004292933A1 (en) 2005-06-09
MXPA06006009A (es) 2006-09-04
CA2547435A1 (en) 2005-06-09
AU2004292933B2 (en) 2011-01-06
RU2006122952A (ru) 2008-01-10
WO2005051424A1 (en) 2005-06-09
US20080267865A1 (en) 2008-10-30
NO20062410L (no) 2006-08-24
KR20070003806A (ko) 2007-01-05
JP2007512324A (ja) 2007-05-17

Similar Documents

Publication Publication Date Title
ATE412432T1 (de) Internalisierende erbb2 antikörper
WO2003048207A3 (en) Anti-dota antibody
BRPI0611800A2 (pt) formulaÇço estÁvel de anticorpo
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE391174T1 (de) Modifizierter tpo-agonisten antikörper
ES2070107T1 (es) Ensayo de antigeno especifico de prostata (psa) libre o complejado.
DK1135498T3 (da) Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
EP2067788A3 (en) Fab fragment libraries and methods for their use
WO2004041865A3 (en) Stabilized single domain antibodies
WO2002030460A3 (en) Therapeutic antibodies
BR0007472A (pt) Agente contendo paramilonas, seco por congelação, sua produção e utilização
BR9712410A (pt) Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado
BR9914430A (pt) Sistemas de agente de aglutinação estáveis em dimensão
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
WO2003007881A3 (en) Antibodies specific for nanotubes and related methods and compositions
ES2162067T3 (es) Composicion de vacuna anti-haemophilus influenzae de tipo b que comprende poli-ribosil-ribitol-fosfato y su procedimiento de preparacion.
BRPI0519399A2 (pt) material de suporte sàlido e mÉtodo para isolamento de anticorpos ou derivados destes
AU1885197A (en) Antibody variants
ES2138102T3 (es) Procedimiento para la deteccion de antigeno urinario asociado a tumores.
BR0001480A (pt) Disco de embreagem
EP2412725A3 (en) Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
MX9401112A (es) Preparacion de conjugados de fotoproteina y metodos para utilizar los mismos.
WO2006102200A3 (en) Docetaxel immunoassay
BR9808729A (pt) Processo para a preparação de um anti-oxidante

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]